{"id":3081,"date":"2026-07-12T13:36:38","date_gmt":"2026-07-12T13:36:38","guid":{"rendered":"https:\/\/usmovingexpertss.com\/?p=3081"},"modified":"2026-07-12T13:36:38","modified_gmt":"2026-07-12T13:36:38","slug":"panic-grips-ionis-pharmaceuticals-investors-amid-bad-news-spree","status":"publish","type":"post","link":"https:\/\/usmovingexpertss.com\/?p=3081","title":{"rendered":"Panic grips Ionis Pharmaceuticals investors amid bad news spree"},"content":{"rendered":"<article><!-- --><!-- --><!-- WPS-5038 -- removed the script from WPS and added the placeholder for trinity player --><!-- --><!-- --><!-- --><!-- --><!-- --><!-- --><!-- CONTENT --><!--[--><!--[--><\/p>\n<p>A single <strong>failed trial<\/strong> can undo years of work in one trading session, and <strong>Ionis Pharmaceuticals<\/strong> (IONS) just went through both <strong>consecutively<\/strong>.<\/p>\n<p>Read more <a href=\"https:\/\/usmovingexpertss.com\/?p=3079\">Lindsey Graham opened up about life during 2016 presidential. Here\u2019s what to know<\/a><\/p>\n<p><!-- --><!--]--><!--[--><\/p>\n<p>Ionis Pharmaceuticals lost <strong>nearly a quarter of its value<\/strong> on <strong>July 9<\/strong> after its heart drug <strong>Wainua failed to meet the primary goal of a late-stage trial<\/strong>. <\/p>\n<p><!-- --><!--]--><!--[--><\/p>\n<p>The next day brought a <strong>second blow<\/strong> from a different corner of Ionis&#8217; drug lineup.<\/p>\n<p><!--]--><!--[--><\/p>\n<p>For anyone holding the stock or watching the wider Healthcare space, the <strong>two-day fall<\/strong> is a reminder of how quickly a biotech project can change.<\/p>\n<p><!-- --><!--]--><!--[--><\/p>\n<h2>Why Ionis stock crashed after the Wainua trial failure<\/h2>\n<p><!-- --><!--]--><!--[--><\/p>\n<p>The trigger was clear. <\/p>\n<p><!-- --><!--]--><!--[--><\/p>\n<p>On July 9, Ionis and partner AstraZeneca (AZN) said their <strong>Phase 3 CARDIO-TTRansform<\/strong>trials of eplontersen, sold as <strong>Wainua<\/strong>, <strong>failed<\/strong> to meet their <strong>primary goal<\/strong> in patients with <strong>ATTR-CM<\/strong>.<\/p>\n<p><!--]--><!--[--><\/p>\n<p>ATTR-CM is a heart disease in which misfolded proteins build up in the heart muscle, making it harder for the heart to pump blood. It is a <strong>large and fast-growing market<\/strong>, which is why the miss stung so much.<\/p>\n<p><!-- --><!--]--><!--[--><\/p>\n<p><strong>More Health Care Stocks:<\/strong><\/p>\n<p><!-- --><!--]--><!--[--><\/p>\n<ul>\n<li><strong>BridgeBio stock jumps after rival heart drug fails key trial<\/strong><\/li>\n<li><strong>Eli Lilly&#8217;s hottest drugs face a quiet new threat<\/strong><\/li>\n<li><strong>Biotech stock sends Wall Street a<\/strong><strong>surprising signal<\/strong><\/li>\n<\/ul>\n<p><!-- --><!--]--><!--[--><\/p>\n<p>The study tested whether adding <strong>Wainua to standard care<\/strong> reduces <strong>cardiovascular deaths <\/strong>and<strong> recurrent heart events over 140 weeks<\/strong>. <\/p>\n<p><!--]--><!--[--><\/p>\n<p>Unfortunately, it did not, Ionis confirmed in its official release.<\/p>\n<p><!-- --><!--]--><!--[--><\/p>\n<p>The stock <strong>fell about 24% that day<\/strong>, sliding from a prior close <strong>near $86 toward $64<\/strong>.<\/p>\n<p><!-- --><!--]--><!--[--><!--]--><!--[--><\/p>\n<p>SOPA Images \/ Getty Images<\/p>\n<p><!-- --><!--]--><!--[--><\/p>\n<h2>How the Roche exit deepened the Ionis selloff<\/h2>\n<p><!-- --><!--]--><!--[--><\/p>\n<p>One bad day can be shrugged off. But two in a row is hard to ignore.<\/p>\n<p><!-- --><!--]--><!--[--><\/p>\n<p>According to BioPharma D\u00ecve, Roche said it was ending <strong>two Huntington&#8217;s disease programs<\/strong> it ran with Ionis on <strong>July 10<\/strong>, including the <strong>antisense drug tominersen<\/strong>. <\/p>\n<p><!--]--><!--[--><\/p>\n<p>Ionis shares fell about <strong>another 8%<\/strong> after the news.<\/p>\n<p><!-- --><!--]--><!--[--><\/p>\n<p>Roche said the <strong>tominersen study<\/strong> did not meet its <strong>performance goal<\/strong>, and a <strong>second early-stage program<\/strong> was stopped over a <strong>safety signal<\/strong> from animal testing.<\/p>\n<p><!-- --><!--]--><!--[--><\/p>\n<p>Stacked together, the two days <strong>erased months of gains<\/strong>. By the <strong>July 10 close<\/strong>, IONS sat <strong>near $58<\/strong>, down <strong>about 29%<\/strong> over <strong>five sessions<\/strong>, 24\/7 Wall St noted.<\/p>\n<p><!--]--><!--[--><\/p>\n<h2>What Wall Street analysts did to Ionis&#8217; price targets<\/h2>\n<p><!-- --><!--]--><!--[--><\/p>\n<p>Analysts moved fast, and almost all of them <strong>cut their target<\/strong>. <\/p>\n<p><!-- --><!--]--><!--[--><\/p>\n<p>However, most <strong>kept their Buy ratings<\/strong>, which tells you they see the damage as contained rather than fatal.<\/p>\n<p><!-- --><!--]--><!--[--><\/p>\n<p><strong>Recent Ionis price target changes<\/strong>:<\/p>\n<p><!-- --><!--]--><!--[--><\/p>\n<ul>\n<li><strong>Jefferies<\/strong>: $113 to $90, Investing.com reported (Buy)<\/li>\n<li><strong>TD Cowen<\/strong>: $108 to $94 (Buy)<\/li>\n<li><strong>Oppenheimer<\/strong>: $110 to $92 (Outperform)<\/li>\n<li><strong>BofA Securities<\/strong>: $111 to $90 (Buy)<\/li>\n<li><strong>Needham<\/strong>: $105 to $86 (Buy)<\/li>\n<\/ul>\n<p><!--]--><!--[--><\/p>\n<p>According to Stocktwits, <strong>BofA Securities<\/strong> called the failure a <strong>big surprise<\/strong> and tied it to a <strong>shifting treatment landscape<\/strong>, as more patients now start on stabilizer drugs early.<\/p>\n<p>Read more <a href=\"https:\/\/usmovingexpertss.com\/?p=3078\">\u2018We shall not see his likes again.\u2019 Here\u2019s what leaders said about Sen. Graham\u2019s death<\/a><\/p>\n<p><!-- --><!--]--><!--[--><\/p>\n<h2>Which rivals gain the most from the Ionis setback<\/h2>\n<p><!-- --><!--]--><!--[--><\/p>\n<p>A drug failure at one company often turns into a win for its competitors. That played out immediately here.<\/p>\n<p><!-- --><!--]--><!--[--><\/p>\n<p>Shares of <strong>Alnylam Pharmaceuticals<\/strong> (ALNY) and <strong>BridgeBio<\/strong> (BBIO) jumped, since the miss <strong>reduces near-term competition<\/strong> in the ATTR-CM market.<\/p>\n<p><!--]--><!--[--><\/p>\n<p>Both companies and <strong>Pfizer<\/strong> (PFE) Inc. already <strong>sell approved heart therapies<\/strong>, so the Wainua trial failure leaves them more <strong>room to grow prescriptions<\/strong>, Benzinga reported.<\/p>\n<p><!-- --><!--]--><!--[--><\/p>\n<h2>Why the broader Ionis business is not broken yet<\/h2>\n<p><!-- --><!--]--><!--[--><\/p>\n<p>Here is the part people panicking tend to skip. Wainua itself is not going away.<\/p>\n<p><!-- --><!--]--><!--[--><\/p>\n<p>The drug is <strong>already approved<\/strong> and <strong>generating revenue<\/strong> in <strong>more than 20 countries<\/strong> for a <strong>separate nerve condition<\/strong>, Yahoo Finance reported. <\/p>\n<p><!--]--><!--[--><\/p>\n<p>The failed study was about <strong>expanding it into heart disease<\/strong>, not defending its current use.<\/p>\n<p><!-- --><!--]--><!--[--><\/p>\n<p>Ionis also posted <strong>first-quarter revenue<\/strong> of <strong>$246 million,<\/strong> and its management guided 2026 revenue to a range of <strong>$875 million to $900 million<\/strong>.<\/p>\n<p><!-- --><!--]--><!--[--><\/p>\n<h2>What Ionis investors should watch over the next few months<\/h2>\n<p><!-- --><!--]--><!--[--><\/p>\n<p>Ionis and AstraZeneca plan to <strong>present the full CARDIO-TTRansform dataset<\/strong> at the European Society of Cardiology Congress in <strong>August<\/strong>, 24\/7 Wall St reported.<\/p>\n<p><!--]--><!--[--><\/p>\n<p>That presentation will show whether a <strong>patient subgroup<\/strong> benefited enough to matter.<\/p>\n<p><!-- --><!--]--><!--[--><\/p>\n<p>A <strong>prespecified subgroup<\/strong> on <strong>Wainua alone<\/strong> did show a small but meaningful risk reduction, so the August readout <strong>could reset expectations<\/strong> either way.<\/p>\n<p><!-- --><!--]--><!--[--><\/p>\n<p>Two later <strong>regulatory decisions<\/strong> on other Ionis drugs are also due before year-end, and each one gives the company a chance to prove the franchise <strong>runs deeper than one heart trial<\/strong>.<\/p>\n<p><!--]--><!--[--><\/p>\n<p><strong>Key takeaways for Ionis investors<\/strong>:<\/p>\n<p><!-- --><!--]--><!--[--><\/p>\n<ul>\n<li><strong>The Wainua ATTR-CM trial failure<\/strong>, not a business collapse, drove the initial 24% drop.<\/li>\n<li><strong>The Roche Huntington&#8217;s exit <\/strong>added a second shock and pushed the five-day loss near 29%.<\/li>\n<li><strong>Most analysts cut targets<\/strong> but kept buy ratings, signaling contained damage.<\/li>\n<li>Watch the August <strong>European Society of Cardiology<\/strong> (<strong>ESC) data<\/strong> and two year-end regulatory decisions for the real reset.<\/li>\n<\/ul>\n<p><!-- --><!--]--><!--[--><\/p>\n<p>None of this makes IONS a clear bargain or a stock to avoid. The next few catalysts decide what happens with the stock going forward.<\/p>\n<p><!-- --><!--]--><!--[--><\/p>\n<p><strong>Related: Lilly quietly hands Chinese partner its cancer drug<\/strong><\/p>\n<p><!--]--><!--[--><\/p>\n<p><i>The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.<\/i><\/p>\n<p>Read more <a href=\"https:\/\/usmovingexpertss.com\/?p=3077\">Lindsey Graham, 71, South Carolina senator, dies after short illness<\/a><\/p>\n<p><!-- --><!--]--><!--]--><!-- --><!-- --><!-- --><!-- --><\/article>\n","protected":false},"excerpt":{"rendered":"<p>A single failed trial can undo years of work in one trading session, and Ionis Pharmaceuticals (IONS) just went through both consecutively.<\/p>\n","protected":false},"author":1,"featured_media":3080,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[14],"tags":[],"class_list":["post-3081","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Panic grips Ionis Pharmaceuticals investors amid bad news spree - US Moving Experts<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/usmovingexpertss.com\/?p=3081\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Panic grips Ionis Pharmaceuticals investors amid bad news spree - US Moving Experts\" \/>\n<meta property=\"og:description\" content=\"A single failed trial can undo years of work in one trading session, and Ionis Pharmaceuticals (IONS) just went through both consecutively.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/usmovingexpertss.com\/?p=3081\" \/>\n<meta property=\"og:site_name\" content=\"US Moving Experts\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-12T13:36:38+00:00\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/usmovingexpertss.com\\\/?p=3081#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/usmovingexpertss.com\\\/?p=3081\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\\\/\\\/usmovingexpertss.com\\\/#\\\/schema\\\/person\\\/d4595f9a47af262eb0de41137cae39b6\"},\"headline\":\"Panic grips Ionis Pharmaceuticals investors amid bad news spree\",\"datePublished\":\"2026-07-12T13:36:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/usmovingexpertss.com\\\/?p=3081\"},\"wordCount\":852,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/usmovingexpertss.com\\\/?p=3081#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/usmovingexpertss.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/f4c669caf78bc43b485f988e604501e7.jpg\",\"articleSection\":[\"Business\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/usmovingexpertss.com\\\/?p=3081#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/usmovingexpertss.com\\\/?p=3081\",\"url\":\"https:\\\/\\\/usmovingexpertss.com\\\/?p=3081\",\"name\":\"Panic grips Ionis Pharmaceuticals investors amid bad news spree - US Moving Experts\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/usmovingexpertss.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/usmovingexpertss.com\\\/?p=3081#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/usmovingexpertss.com\\\/?p=3081#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/usmovingexpertss.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/f4c669caf78bc43b485f988e604501e7.jpg\",\"datePublished\":\"2026-07-12T13:36:38+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/usmovingexpertss.com\\\/#\\\/schema\\\/person\\\/d4595f9a47af262eb0de41137cae39b6\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/usmovingexpertss.com\\\/?p=3081#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/usmovingexpertss.com\\\/?p=3081\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/usmovingexpertss.com\\\/?p=3081#primaryimage\",\"url\":\"https:\\\/\\\/usmovingexpertss.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/f4c669caf78bc43b485f988e604501e7.jpg\",\"contentUrl\":\"https:\\\/\\\/usmovingexpertss.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/f4c669caf78bc43b485f988e604501e7.jpg\",\"width\":1200,\"height\":675},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/usmovingexpertss.com\\\/?p=3081#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/usmovingexpertss.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Panic grips Ionis Pharmaceuticals investors amid bad news spree\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/usmovingexpertss.com\\\/#website\",\"url\":\"https:\\\/\\\/usmovingexpertss.com\\\/\",\"name\":\"US Moving Experts\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/usmovingexpertss.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/usmovingexpertss.com\\\/#\\\/schema\\\/person\\\/d4595f9a47af262eb0de41137cae39b6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/50b1ad2e498f523425ee0a8cc5180a210646db1622662a3d56cc405d3e0c346a?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/50b1ad2e498f523425ee0a8cc5180a210646db1622662a3d56cc405d3e0c346a?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/50b1ad2e498f523425ee0a8cc5180a210646db1622662a3d56cc405d3e0c346a?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"sameAs\":[\"http:\\\/\\\/usmovingexpertss.com\"],\"url\":\"https:\\\/\\\/usmovingexpertss.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Panic grips Ionis Pharmaceuticals investors amid bad news spree - US Moving Experts","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/usmovingexpertss.com\/?p=3081","og_locale":"en_US","og_type":"article","og_title":"Panic grips Ionis Pharmaceuticals investors amid bad news spree - US Moving Experts","og_description":"A single failed trial can undo years of work in one trading session, and Ionis Pharmaceuticals (IONS) just went through both consecutively.","og_url":"https:\/\/usmovingexpertss.com\/?p=3081","og_site_name":"US Moving Experts","article_published_time":"2026-07-12T13:36:38+00:00","author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/usmovingexpertss.com\/?p=3081#article","isPartOf":{"@id":"https:\/\/usmovingexpertss.com\/?p=3081"},"author":{"name":"admin","@id":"https:\/\/usmovingexpertss.com\/#\/schema\/person\/d4595f9a47af262eb0de41137cae39b6"},"headline":"Panic grips Ionis Pharmaceuticals investors amid bad news spree","datePublished":"2026-07-12T13:36:38+00:00","mainEntityOfPage":{"@id":"https:\/\/usmovingexpertss.com\/?p=3081"},"wordCount":852,"commentCount":0,"image":{"@id":"https:\/\/usmovingexpertss.com\/?p=3081#primaryimage"},"thumbnailUrl":"https:\/\/usmovingexpertss.com\/wp-content\/uploads\/2026\/07\/f4c669caf78bc43b485f988e604501e7.jpg","articleSection":["Business"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/usmovingexpertss.com\/?p=3081#respond"]}]},{"@type":"WebPage","@id":"https:\/\/usmovingexpertss.com\/?p=3081","url":"https:\/\/usmovingexpertss.com\/?p=3081","name":"Panic grips Ionis Pharmaceuticals investors amid bad news spree - US Moving Experts","isPartOf":{"@id":"https:\/\/usmovingexpertss.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/usmovingexpertss.com\/?p=3081#primaryimage"},"image":{"@id":"https:\/\/usmovingexpertss.com\/?p=3081#primaryimage"},"thumbnailUrl":"https:\/\/usmovingexpertss.com\/wp-content\/uploads\/2026\/07\/f4c669caf78bc43b485f988e604501e7.jpg","datePublished":"2026-07-12T13:36:38+00:00","author":{"@id":"https:\/\/usmovingexpertss.com\/#\/schema\/person\/d4595f9a47af262eb0de41137cae39b6"},"breadcrumb":{"@id":"https:\/\/usmovingexpertss.com\/?p=3081#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/usmovingexpertss.com\/?p=3081"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/usmovingexpertss.com\/?p=3081#primaryimage","url":"https:\/\/usmovingexpertss.com\/wp-content\/uploads\/2026\/07\/f4c669caf78bc43b485f988e604501e7.jpg","contentUrl":"https:\/\/usmovingexpertss.com\/wp-content\/uploads\/2026\/07\/f4c669caf78bc43b485f988e604501e7.jpg","width":1200,"height":675},{"@type":"BreadcrumbList","@id":"https:\/\/usmovingexpertss.com\/?p=3081#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/usmovingexpertss.com\/"},{"@type":"ListItem","position":2,"name":"Panic grips Ionis Pharmaceuticals investors amid bad news spree"}]},{"@type":"WebSite","@id":"https:\/\/usmovingexpertss.com\/#website","url":"https:\/\/usmovingexpertss.com\/","name":"US Moving Experts","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/usmovingexpertss.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/usmovingexpertss.com\/#\/schema\/person\/d4595f9a47af262eb0de41137cae39b6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/50b1ad2e498f523425ee0a8cc5180a210646db1622662a3d56cc405d3e0c346a?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/50b1ad2e498f523425ee0a8cc5180a210646db1622662a3d56cc405d3e0c346a?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/50b1ad2e498f523425ee0a8cc5180a210646db1622662a3d56cc405d3e0c346a?s=96&d=mm&r=g","caption":"admin"},"sameAs":["http:\/\/usmovingexpertss.com"],"url":"https:\/\/usmovingexpertss.com\/?author=1"}]}},"_links":{"self":[{"href":"https:\/\/usmovingexpertss.com\/index.php?rest_route=\/wp\/v2\/posts\/3081","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/usmovingexpertss.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/usmovingexpertss.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/usmovingexpertss.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/usmovingexpertss.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3081"}],"version-history":[{"count":0,"href":"https:\/\/usmovingexpertss.com\/index.php?rest_route=\/wp\/v2\/posts\/3081\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/usmovingexpertss.com\/index.php?rest_route=\/wp\/v2\/media\/3080"}],"wp:attachment":[{"href":"https:\/\/usmovingexpertss.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3081"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/usmovingexpertss.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3081"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/usmovingexpertss.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3081"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}